Commenting on NICE and NHS England’s decision to fund Novartis’ Kymriah for patients up to 25 years old with a certain type of leukemia, BIA CEO, Steve Bates, said:
“Today’s decisions by NICE NHS England shows that the UK is well set to be the best country in the world in which to invent, trial, develop, manufacture and market next generation CAR-T cell cancer therapies.
The Department of Health has today written to pharmaceutical companies on the EU Exit – Human medicines supply in a March 2019 ‘no deal’ scenario. The letter details government contingency plans to stockpile medicines to cope with any potential delays at the border that may arise in the short term.
The UK Government has today released a series of 25 technical notices that offer guidance for business on what will happen in a ‘no deal’ Brexit. The notices were launched following a speech by Brexit Secretary Dominic Raab.
Parliament has voted in favour of amendment NC17 to the Trade Bill that will make it a negotiating objective for the UK Government to seek the UK's participation in the European medicines regulatory network.
The BIA has to responded to the announcement from government of the inaugural UKRI Future Leaders Fellowship Scheme will receive £900 million over the next 11 years.
BIA CEO Steve Bates said: “Today’s announcement will help to boost innovation in the UK and I am delighted to see that businesses will be able to use this scheme. It is vital that the UK government continues to support young entrepreneurs and business leaders to secure the innovation pipeline in the UK for the future.”
The BIA welcomes the creation of British Patient Capital, a £2.5 billion fund launched today by the British Business Bank. The fund will provide long-term funding to support the growth of innovative UK bioscience companies and other sectors.
Today the Industrial Biotechnology Leadership Forum (IBLF) launches the new ‘National Industrial Biotechnology Strategy to 2030’, promoted in partnership with the UK BioIndustry Association (BIA). The Strategy has been developed by the IBLF and two collaborative networks in industrial biotech, CBMNet and BIOCATNET.